Corvus Pharmaceuticals (CRVS) News Today $7.35 +0.19 (+2.65%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$7.32 -0.03 (-0.39%) As of 10/24/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 8.7% - Here's WhyOctober 18, 2025 | marketbeat.comAnalysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Price Target at $13.75October 18, 2025 | americanbankingnews.comWall Street Zen Downgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to SellOctober 18, 2025 | marketbeat.comCorvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European ...October 17, 2025 | finance.yahoo.comCorvus Pharmaceuticals Presents Promising Interim Data for Ciforadenant in Combination Therapy for Metastatic Renal Cell Carcinoma at ESMO Congress 2025October 17, 2025 | quiverquant.comQCorvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025October 17, 2025 | globenewswire.comCorvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by BarclaysOctober 14, 2025 | marketbeat.comBarclays Initiates Coverage of Corvus Pharmaceuticals (CRVS) with Overweight RecommendationOctober 14, 2025 | msn.comCorvus Pharmaceuticals initiated with an Overweight at BarclaysOctober 13, 2025 | msn.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by AnalystsOctober 13, 2025 | marketbeat.comEmpirical Financial Services LLC d.b.a. Empirical Wealth Management Invests $672,000 in Corvus Pharmaceuticals, Inc. $CRVSOctober 6, 2025 | marketbeat.comCorvus Pharmaceuticals Appoints David Moore as DirectorOctober 3, 2025 | msn.comCorvus Pharmaceuticals Appoints David Moore to Board of DirectorsOctober 2, 2025 | finance.yahoo.comCorvus Pharmaceuticals Appoints David Moore to Board of DirectorsOctober 2, 2025 | globenewswire.comCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 6.1% - Should You Buy?September 26, 2025 | marketbeat.comSamlyn Capital LLC Decreases Stock Position in Corvus Pharmaceuticals, Inc. $CRVSSeptember 8, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. $CRVS Position Increased by American Century Companies Inc.September 8, 2025 | marketbeat.comJump Financial LLC Invests $143,000 in Corvus Pharmaceuticals, Inc. $CRVSSeptember 7, 2025 | marketbeat.comWellington Management Group LLP Takes $333,000 Position in Corvus Pharmaceuticals, Inc. $CRVSSeptember 3, 2025 | marketbeat.comEntryPoint Capital LLC Decreases Stake in Corvus Pharmaceuticals, Inc. $CRVSAugust 27, 2025 | marketbeat.comCantor Fitzgerald Brokers Cut Earnings Estimates for CRVSAugust 16, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for CRVS Q3 Earnings?August 16, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for CRVS FY2028 EarningsAugust 15, 2025 | marketbeat.comCorvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 CatalystsAugust 12, 2025 | seekingalpha.comCorvus Pharmaceuticals (NASDAQ:CRVS) Raised to Hold at Wall Street ZenAugust 10, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comCorvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) top owners are retail investors with 48% stake, while 33% is held by institutionsAugust 5, 2025 | finance.yahoo.comCorvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director Peter A. Thompson Sells 1,176,332 SharesJuly 1, 2025 | marketbeat.comCompanies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comCantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)June 14, 2025 | theglobeandmail.comCorvus Nicks up on Releasing Preclinical Trial DataJune 11, 2025 | baystreet.ca3 Penny Stocks Wall Street Sees With 243% UpsideJune 11, 2025 | 247wallst.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Bank of America Corp DEJune 11, 2025 | marketbeat.comCantor Fitzgerald Estimates CRVS FY2026 EarningsJune 10, 2025 | marketbeat.comSquarepoint Ops LLC Increases Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)June 5, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest UpdateJune 4, 2025 | marketbeat.comCorvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisJune 4, 2025 | globenewswire.comCorvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comOMERS ADMINISTRATION Corp Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 2,532,718 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 20, 2025 | marketbeat.comSphera Funds Management LTD. Acquires New Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 18, 2025 | marketbeat.comRTW Investments LP Invests $14.34 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 18, 2025 | marketbeat.comBridgeway Capital Management LLC Has $221,000 Stock Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 15, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Raised to "Hold" at StockNews.comMay 14, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Schonfeld Strategic Advisors LLCMay 12, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Barclays PLCMay 11, 2025 | marketbeat.comCorvus Pharmaceuticals Shares Surge on Study Data Evaluating SoquelitinibMay 10, 2025 | marketwatch.comDeerfield Management Company L.P. Series C Invests $5.35 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 10, 2025 | marketbeat.com Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼0.630.93▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼23▲CRVS Articles Average Week Get the Latest News and Ratings for CRVS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Corvus Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Ocular Therapeutix News ANI Pharmaceuticals News Twist Bioscience News Vera Therapeutics News Cogent Biosciences News Biohaven News Stoke Therapeutics News Vericel News Arcus Biosciences News AbCellera Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts